2025-01-31 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Review

**1. Performance Relative to S&P 500 (VOO):**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases.

The cumulative return of VRTX is 149.16%, significantly outperforming the S&P 500's cumulative return of 121.09%.  The difference is 28.1 percentage points.  This places the relative outperformance at the 58.9th percentile based on historical data, indicating a strong relative performance compared to the S&P 500.  However,  the relative performance metric should be considered in context with the provided risk metrics (MDD, Beta).

The provided CAGR data shows high growth rates in certain periods, followed by periods of lower or even negative growth, highlighting the volatility inherent in biotech investments.  The consistently positive alpha suggests that VRTX has historically outperformed the market beyond what would be expected given its beta (market risk exposure).  The increasing beta from 2015 to 2023 indicates increasing sensitivity to market fluctuations.


**2. Recent Price Movement:**

* **Closing Price:** $438.40
* **5-Day Moving Average:** $440.82
* **20-Day Moving Average:** $421.80
* **60-Day Moving Average:** $446.94

The stock price is currently below its 5-day and 60-day moving averages, indicating a short-term downtrend, but above its 20-day moving average, suggesting potential short-term support. The recent price change of -$0.71 reflects a minor daily decline.


**3. Technical Indicators and Expected Return:**

* **RSI:** 71.11 (Approaching overbought territory, suggesting potential near-term correction.)
* **PPO:** 0.9972 (Positive, indicating bullish momentum.)
* **Delta_Previous_Relative_Divergence:** 0.6 (+), indicating short-term upward momentum.
* **Expected Return:** 24.6% over the long term (2+ years) relative to the S&P 500. This suggests a significant outperformance potential for long-term investors.


**4. Recent Earnings Analysis:**

The EPS figures are highly volatile.  While Q1 2024 and Q3 2024 showed strong EPS, Q2 2024 experienced a significant negative EPS.  Revenue shows consistent growth, but the profitability is influenced by the fluctuating EPS.  Further investigation is needed into the causes of such large EPS swings to better understand the financial health of the company.  Note that there is duplicated data (2024-11-05) in the provided table.


| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-11-05 | 4.05    | $2.77 B      |
| 2024-08-02 | -13.92  | $2.65 B      |
| 2024-05-07 | 4.26    | $2.69 B      |
| 2023-11-07 | 4.01    | $2.48 B      |
| 2024-11-05 | 4.01    | $2.48 B      | *(Duplicate Data)*


**5. Financial Information:**

The revenue shows a steady growth trend.  Profit margins are consistently high, indicating strong profitability. However, the Equity and ROE figures show significant volatility,  with a substantial negative ROE in Q2 2024. This requires further investigation to understand the underlying causes.

| Quarter    | Revenue  | Profit Margin | Equity     | ROE       |
|------------|----------|---------------|------------|-----------|
| 2024-09-30 | $2.77B   | 85.84%        | $15.63B   | 6.69%     |
| 2024-06-30 | $2.65B   | 85.94%        | $14.77B   | -24.32%   |
| 2024-03-31 | $2.69B   | 87.27%        | $18.55B   | 5.93%     |
| 2023-12-31 | $2.52B   | 85.38%        | $17.58B   | 5.51%     |
| 2023-09-30 | $2.48B   | 87.17%        | $16.51B   | 6.27%     |


**7. Overall Analysis:**

VRTX demonstrates strong long-term growth potential, significantly outperforming the S&P 500 over the past period. However, there is considerable volatility in both price and earnings. The high RSI suggests the stock might be overbought in the short term, hinting at a potential correction. The large negative EPS in Q2 2024 and the volatility in ROE requires further investigation.  Long-term investors with a high risk tolerance could consider VRTX, but thorough due diligence and a focus on the underlying drivers of the company's earnings are crucial.  A closer look at the causes of the EPS and ROE fluctuations are needed before making any investment decision.


**8. Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice.  Always conduct thorough research and consult with a qualified financial advisor before making any investment decisions.
